The Healing Power of Botanical Therapeutics®


Social Media & Investor Awareness Programs Lead Herborium Group to 40% Record Increase in Preliminary 2nd Quarter Revenues; Website Traffic Up 87% Shares buyback to commence this month

Press Release: Herborium Group, Inc. – Mon, May 7, 2012 8:45 AM EDT

TEANECK, N.J., May 7, 2012 /PRNewswire/ -- Herborium Group, Inc., (PINKS. HBRM), a Botanical Therapeutics® company, reports today, that preliminary 2nd quarter 2012 revenue sustained a record breaking increase of 40% for its first two months, in comparison to the same two months of 2011.  This most satisfying sales growth is largely the result of an aggressive Social Media Marketing Strategy introduced by the Company in the fall of 2011. The same marketing efforts brought on 87% increase in the traffic, a designated website for Herborium's unique, all botanical ingredients based acne product targeting over 135 million acne sufferers in US and Europe. Herborium's Investor Awareness Program has also contributed to this growth.  

Dr. Agnes Olszewski, Herborium's Chairmen and CEO stated:  "I am extremely pleased with these preliminary results that indicate that our 2012 sales revenues should achieve significant all year increase as we enter into several exciting new markets for our current and new products. Social Media Marketing initiatives along with our February 2012 announced Investor Awareness programs will continue to have a significant upward impact on our revenues and share price."

"Increase in revenue is an important factor that should allow the Company to move forward with number of initiatives including the repurchasing of shares announced in our April 23rd, 2012 Press Release. Shareholder value is very important to us as we make strides into new revenue streams and we will continue to update our shareholders of our progress moving forward," concluded Dr. Olszewski.

About Herborium Group, Inc.

Herborium Group, Inc., a Botanical Therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company uses clinical validation to establish and maintain a differential advantage. The company markets its products in the US and Europe. For more information, please visit and

One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.

For more information please inquire:

Information provided on about medical conditions, symptoms, and related products is not intended to be a substitute for professional medical advice. Visitors to this site should not use this information to diagnose or treat a health problem, symptom, concern or disease without consulting with their individual qualified healthcare provider. Statements contained on this website have not been evaluated by the FDA. Herborium products are not intended to diagnose, heal, cure or prevent disease.